PREFERENCE FOR RITUXIMAB SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) AMONG PATIENTS WITH CD20+ NON-HODGKIN'S LYMPHOMA (NHL) COMPLETING THE RASQ MEASURE IN RANDOMIZED PHASE III STUDIES PREFMAB AND MABCUTE
Author(s)
Rule S1, Briones J2, Smith R3, Theodore Oklota C4, Ngoh CA3, Osborne S3, Capochiani E5, Rummel M6
1Derriford Hospital, Plymouth, UK, 2Santa Creu i Sant Pau Hospital, Barcelona, Spain, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Genentech, South San Francisco, CA, USA, 5Centro Aziendale di Ematologia, Livorno, Italy, 6University Hospital Giessen and Marburg, Giessen, Germany
OBJECTIVES: Rituximab SC reduces administration times (~5 minutes) compared with the IV route (~4 hours). We examined the extent of patient preference for rituximab SC versus IV in the PrefMab and MabCute studies using the Rituximab Administration Satisfaction Questionnaire (RASQ). METHODS: In PrefMab (NCT01724021) patients with untreated CD20+ DLBCL/FL received 1 cycle of IV rituximab (375mg/m) followed by either SC rituximab (1400mg, x3) then IV rituximab (x4), or IV rituximab (x3) then SC rituximab (x4), with chemotherapy. In MabCute (NCT01461928) patients with relapsed/refractory CD20+ indolent NHL received induction rituximab IV (375mg/m;1 cycle) then rituximab SC (1400mg;cycles 2–8) plus 6–8 chemotherapy cycles. RASQ evaluated preference by assessing patients’ perceptions of the impact of administration route and treatment satisfaction. Conceptual validation of RASQ has been conducted and psychometric data will be reported. RESULTS: Median RASQ scores for PrefMab were: convenience IV (n=211) 58.3 (interquartile range: 41.7–75.0) and SC (n=207) 83.3(75.0–91.7); satisfaction: IV (n=211) 75.0(62.5–87.5), SC (n=208) 87.5(75.0–100.0); impact on daily life: IV (n=145) 50.0(41.7–83.3), SC (n=163) 83.3(83.3–100.0); physical impact IV (n=211) 83.3(66.7–100.0), SC (n=208) 83.3(75.0–100.0); psychological impact IV (n=211) 80.0(65.0–90.0), SC (n=208) 88.8(75.0–95.0). SC administration was preferred by 80.3% and 85.9% of patients with IV or SC as most recent dose, respectively. Results were similar irrespective of treatment sequence. Median RASQ scores for MabCute (n=92) were: convenience: IV 58.3 (33.3–66.7), SC 83.3 (66.7–83.3); satisfaction: IV 62.5(50.0–87.5), SC 87.5(75.0–100.0); impact on daily life: IV 58.3(41.7–66.7), SC 83.3(66.7–83.3); physical impact IV 75.0(66.7–91.7), SC 83.3(66.7–91.7); psychological impact IV 70.0(60.0–85.0), SC 85.0(75.0–95.0). CONCLUSIONS: Consistent patient satisfaction and preference for SC versus IV rituximab was demonstrated in the PrefMab and MabCute studies. RASQ is a reliable and valid measure of patient treatment preference.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PSY89
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Stated Preference & Patient Satisfaction
Disease
Systemic Disorders/Conditions